#5 - Regeneron Pharmaceuticals (NASDAQ:REGN)
In terms of share price, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is the most expensive stock on this list of low-beta stocks. But that doesn’t mean that it doesn’t deserve your consideration. Although it has several products that are commercially available, many investors may not have been familiar with the company until it made headlines for its monoclonal antibody to treat Covid-19.
However, when it comes to companies like Regeneron, it all comes down to the pipeline. Regeneron has an extensive pipeline including many candidates currently in Phase 3 trials. And among those in early-stage trials is NTLA-2001 which the company is co-developing with Intellia Therapeutics, Inc. (NASDAQ: NTLA) using the CRISPR-Cas9 genome editing technology.
Regeneron does not issue a dividend which may be enough to keep some investors away. However, REGN stock has grown over 16% in the last 12 months, and analysts still see some upside ahead.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More - Current Price
- $738.00
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 18 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $1,099.55 (49.0% Upside)
